Neoprobe cuts staff after regulatory rebuffs:
This article was originally published in Clinica
Executive Summary
Neoprobe is to cut staff by 20% in order to reduce its 1998 projected losses to $12 million. The US company wishes to see operating costs fall by 30%, from $30.4 million. Last year European approval for the RIGScan CR49 antibody colorectal cancer detection was delayed (see Clinica No 766, p 16) and in January the FDA requested further information on side effects of the radioactive-tagged marker (see Clinica No 790, p 12).